25.01.2023 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that it will stop the Phase 3 KEYNOTE-991 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with enzalutamide and androgen deprivation .
22.12.2022 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd), a clinical-stage biotech company focused on biologic and small molecule discovery and . Seite 1
Shares of Merck and Moderna jumped Tuesday after the drugmakers said a potential skin cancer vaccine they are developing using the same technology behind COVID-19 preventive shots fared well in
The push comes as the World Health Organisation also raised concerns that China's 1.4 billion population was not adequately vaccinated and the United States offered help in dealing with a surge in infections. India's Indegene files for IPO, Carlyle to sell stake Carlyle-backed Indian life science technology company Indegene Ltd has filed for an initial public offering, draft papers submitted to the country's market regulator showed on Thursday.